JP2010529026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529026A5 JP2010529026A5 JP2010510385A JP2010510385A JP2010529026A5 JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5 JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- booster
- human
- peptide
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 43
- 230000000240 adjuvant Effects 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 9
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 102100016662 ERBB2 Human genes 0.000 claims 3
- 101700025368 ERBB2 Proteins 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 101710037934 QRSL1 Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 230000036039 immunity Effects 0.000 claims 3
- 230000002055 immunohistochemical Effects 0.000 claims 3
- 230000001681 protective Effects 0.000 claims 3
- 229960005486 vaccines Drugs 0.000 claims 3
- 210000000265 Leukocytes Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000001809 detectable Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Claims (34)
- 被験体における乳癌再発に対する防御免疫または治療免疫を誘導するための、製薬上有効な担体と配列番号2のアミノ酸配列を有するペプチドとを含む組成物。
- 注射または接種により投与される、請求項1記載の組成物。
- 該注射が皮内注射である、請求項2記載の組成物。
- 1以上の分割用量として注射される、請求項2記載の組成物。
- 該用量が該ペプチドの最適化量を含有する、請求項4記載の組成物。
- 身体上の複数の注射部位が互いに約5cm離れて位置する、請求項4記載の組成物。
- 防御免疫が確立されるまで6ヶ月にわたって6回投与される、請求項1記載の組成物。
- 被験体における乳癌再発に対する防御免疫または治療免疫を誘導するための、製薬上有効な担体と配列番号2を有するペプチドとを含むワクチンブースター組成物の有効量を含むブースター組成物であって、請求項1〜7のいずれか1項記載の組成物の投与を受けた被験体に更に投与される、前記ブースター組成物。
- 注射により投与される、請求項8記載のブースター組成物。
- 該注射が皮内注射である、請求項9記載のブースター組成物。
- 1以上の別個の用量で注射される、請求項8記載のブースター組成物。
- 2つの用量が等濃度の該ペプチドを含有する、請求項11記載のブースター組成物。
- 身体上の複数の注射部位が互いに約5cm離れて位置する、請求項11記載のブースター組成物。
- 一次免疫スケジュールが完了した後、6ヶ月または12ヶ月ごとに投与される、請求項8記載のブースター組成物。
- 被験体がヒトである、請求項1記載の組成物。
- 該ヒトがヒト白血球抗原A2を発現する、請求項15記載の組成物。
- 該ヒトがヒト白血球抗原A3を発現する、請求項15記載の組成物。
- 該ヒトが、検出可能なレベルのHER2/neuを発現する、請求項15記載の組成物。
- 該ヒトが、HER2/neu遺伝子発現に関して、タンパク質発現1+または2+の免疫組織化学（IHC）評価、および約0より大きく約2.0未満の蛍光in situハイブリダイゼーション（FISH）評価を有する、請求項18記載の組成物。
- 該ヒトが、HER2/neu遺伝子発現に関して、過剰発現3+の免疫組織化学（IHC）評価および約2.0より大きな蛍光in situハイブリダイゼーション（FISH）評価を有する、請求項18記載の組成物。
- 該被験体が、節陽性または節陰性乳癌の診断後に完全な臨床的寛解の状態にある、請求項1記載の組成物。
- 該被験体が乳癌に関して部分的な臨床的寛解の状態にある、請求項1記載の組成物。
- アジュバントを更に含む、請求項1記載の組成物。
- 該アジュバントが組換えヒト顆粒球マクロファージ-コロニー刺激因子である、請求項23記載の組成物。
- 該ワクチンブースター組成物がアジュバントを更に含む、請求項8記載のブースター組成物。
- 該アジュバントが組換えヒト顆粒球マクロファージ-コロニー刺激因子である、請求項23記載の組成物。
- 投与されると、配列番号2のアミノ酸配列を有するペプチドに対する細胞傷害性Tリンパ球応答を誘導する、請求項1記載の組成物。
- 該ヒトが節陽性乳癌を有していた、請求項15記載の組成物。
- 該ヒトが節陰性乳癌を有していた、請求項15記載の組成物。
- 製薬上許容される担体、配列番号2のアミノ酸配列を有するペプチドの有効量およびアジュバントを含んでなるワクチン組成物。
- 該アジュバントが顆粒球マクロファージ-コロニー刺激因子である、請求項30記載の組成物。
- 該ペプチドの有効量が1mg/mlであり、該アジュバントの用量が0.1〜0.5mg/mlである、請求項30記載の組成物。
- 該ペプチドの有効量が1mg/mlであり、該アジュバントの用量が0.25mg/mlである、請求項30記載の組成物。
- 該ペプチドの有効量が1mg/mlであり、該アジュバントの用量が0.125mg/mlである、請求項30記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94152407P | 2007-06-01 | 2007-06-01 | |
| US60/941,524 | 2007-06-01 | ||
| PCT/US2008/060044 WO2008150577A1 (en) | 2007-06-01 | 2008-04-11 | Vaccine for the prevention of breast cancer relapse |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138567A Division JP6097724B2 (ja) | 2007-06-01 | 2014-07-04 | 乳癌再発の予防のためのワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529026A JP2010529026A (ja) | 2010-08-26 |
| JP2010529026A5 true JP2010529026A5 (ja) | 2011-04-28 |
| JP5635399B2 JP5635399B2 (ja) | 2014-12-03 |
Family
ID=40094045
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510385A Active JP5635399B2 (ja) | 2007-06-01 | 2008-04-11 | 乳癌再発の予防のためのワクチン |
| JP2014138567A Expired - Fee Related JP6097724B2 (ja) | 2007-06-01 | 2014-07-04 | 乳癌再発の予防のためのワクチン |
| JP2016211150A Pending JP2017071607A (ja) | 2007-06-01 | 2016-10-28 | 乳癌再発の予防のためのワクチン |
| JP2018153050A Active JP7072467B2 (ja) | 2007-06-01 | 2018-08-16 | 乳癌再発の予防のためのワクチン |
| JP2020161232A Pending JP2021001218A (ja) | 2007-06-01 | 2020-09-25 | 乳癌再発の予防のためのワクチン |
| JP2022068170A Pending JP2022095926A (ja) | 2007-06-01 | 2022-04-18 | 乳癌再発の予防のためのワクチン |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138567A Expired - Fee Related JP6097724B2 (ja) | 2007-06-01 | 2014-07-04 | 乳癌再発の予防のためのワクチン |
| JP2016211150A Pending JP2017071607A (ja) | 2007-06-01 | 2016-10-28 | 乳癌再発の予防のためのワクチン |
| JP2018153050A Active JP7072467B2 (ja) | 2007-06-01 | 2018-08-16 | 乳癌再発の予防のためのワクチン |
| JP2020161232A Pending JP2021001218A (ja) | 2007-06-01 | 2020-09-25 | 乳癌再発の予防のためのワクチン |
| JP2022068170A Pending JP2022095926A (ja) | 2007-06-01 | 2022-04-18 | 乳癌再発の予防のためのワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8222214B2 (ja) |
| EP (2) | EP2722336A1 (ja) |
| JP (6) | JP5635399B2 (ja) |
| KR (5) | KR101572474B1 (ja) |
| CN (2) | CN101678093A (ja) |
| AU (1) | AU2008260399C1 (ja) |
| CA (1) | CA2687368C (ja) |
| CY (1) | CY1114912T1 (ja) |
| DK (1) | DK2162149T3 (ja) |
| ES (1) | ES2445399T3 (ja) |
| HR (1) | HRP20140102T1 (ja) |
| MX (1) | MX2009012858A (ja) |
| PL (1) | PL2162149T3 (ja) |
| PT (1) | PT2162149E (ja) |
| SI (1) | SI2162149T1 (ja) |
| WO (1) | WO2008150577A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| MX2009012858A (es) * | 2007-06-01 | 2010-02-03 | Jackson H M Found Military Med | Vacuna para la prevencion de recaidas de cancer de seno. |
| WO2010068647A1 (en) | 2008-12-10 | 2010-06-17 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine for the prevention of breast cancer recurrence |
| CA2864841C (en) | 2012-02-17 | 2020-07-07 | Keith L. Knutson | Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide |
| US10028918B2 (en) | 2012-05-08 | 2018-07-24 | Albert Einstein College Of Medicine, Inc. | Nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine and uses thereof |
| CN115093480A (zh) | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| RU2014102948A (ru) * | 2013-02-05 | 2015-08-10 | Нитто Денко Корпорейшн | Вакцинная композиция для мукозального введения |
| KR20140100415A (ko) * | 2013-02-05 | 2014-08-14 | 닛토덴코 가부시키가이샤 | 경피 투여용 백신 조성물 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| CN104513293A (zh) * | 2013-09-26 | 2015-04-15 | 深圳信立泰药业股份有限公司 | 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 |
| US20160258951A1 (en) * | 2013-10-28 | 2016-09-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of monitoring immune responses |
| US10434152B2 (en) * | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| EA037855B1 (ru) | 2016-01-29 | 2021-05-27 | Сорренто Терапьютикс, Инк. | Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1 |
| WO2017210255A1 (en) * | 2016-05-31 | 2017-12-07 | Galena Biopharma, Inc. | Vaccine therapy for treatment of endometrial and ovarian cancer |
| AU2019364258A1 (en) * | 2018-10-21 | 2021-06-03 | Slsg Limited Llc | Combination immunotherapy for treatment of triple-negative breast cancer |
| KR20240006547A (ko) | 2021-05-04 | 2024-01-15 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
| KR20230017640A (ko) | 2021-07-28 | 2023-02-06 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| DE69031120T2 (de) * | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
| US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| JPH10510988A (ja) * | 1994-12-14 | 1998-10-27 | ザ スクリップス リサーチ インスティテュート | 腫瘍−特異的細胞毒性ｔ細胞のインビボ活性化 |
| US6514942B1 (en) * | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| US20030022820A1 (en) * | 1995-12-14 | 2003-01-30 | Linda A. Sherman | In vivo activation of tumor-specific cytotoxic t cells |
| US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| US7060284B1 (en) * | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| US6984384B1 (en) * | 1999-09-30 | 2006-01-10 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| US20070098776A1 (en) * | 1999-12-13 | 2007-05-03 | Fikes John D | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20030224036A1 (en) * | 1999-12-13 | 2003-12-04 | Fikes John D | Hla class I a2 tumor associated antigen peptides and vaccine compositions |
| US6602510B1 (en) * | 2000-04-05 | 2003-08-05 | Epimmune Inc. | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20040121946A9 (en) * | 2000-12-11 | 2004-06-24 | John Fikes | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| AU2002318186A1 (en) * | 2001-07-03 | 2003-01-21 | Lexicon Genetics Incorporated | Novel human kielin-like proteins and polynucleotides encoding the same |
| CA2452382A1 (en) * | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| US20030049253A1 (en) * | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| WO2003076585A2 (en) | 2002-03-08 | 2003-09-18 | Board Of Regents, The University Of Texas System | Controlled modulation of amino acid side chain length of peptide antigens |
| KR100555211B1 (ko) * | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신 |
| CN1720060B (zh) * | 2002-10-03 | 2011-12-14 | 惠氏控股公司 | 人乳头瘤病毒多肽和免疫原性组合物 |
| US20070135335A1 (en) | 2003-02-10 | 2007-06-14 | Autogen Research Pty Ltd. | Therapeutic molecules |
| US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005014634A1 (en) | 2003-08-12 | 2005-02-17 | Agt Biosciences Limited | A gene and uses therefor |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| US20060275777A1 (en) * | 2005-06-03 | 2006-12-07 | Waelti Ernst R | Novel strategies for protein vaccines |
| MX2009012858A (es) * | 2007-06-01 | 2010-02-03 | Jackson H M Found Military Med | Vacuna para la prevencion de recaidas de cancer de seno. |
-
2008
- 2008-04-11 MX MX2009012858A patent/MX2009012858A/es active IP Right Grant
- 2008-04-11 KR KR1020097027587A patent/KR101572474B1/ko active IP Right Grant
- 2008-04-11 JP JP2010510385A patent/JP5635399B2/ja active Active
- 2008-04-11 CN CN200880018401A patent/CN101678093A/zh active Pending
- 2008-04-11 DK DK08745615.8T patent/DK2162149T3/da active
- 2008-04-11 WO PCT/US2008/060044 patent/WO2008150577A1/en active Application Filing
- 2008-04-11 EP EP13191663.7A patent/EP2722336A1/en not_active Ceased
- 2008-04-11 KR KR1020157007937A patent/KR101863534B1/ko active IP Right Grant
- 2008-04-11 CA CA2687368A patent/CA2687368C/en active Active
- 2008-04-11 CN CN201610201242.6A patent/CN105816867A/zh active Pending
- 2008-04-11 KR KR1020217023573A patent/KR20210097209A/ko active IP Right Grant
- 2008-04-11 ES ES08745615.8T patent/ES2445399T3/es active Active
- 2008-04-11 KR KR1020187014920A patent/KR102079921B1/ko active IP Right Grant
- 2008-04-11 SI SI200831143T patent/SI2162149T1/sl unknown
- 2008-04-11 EP EP08745615.8A patent/EP2162149B1/en active Active
- 2008-04-11 PL PL08745615T patent/PL2162149T3/pl unknown
- 2008-04-11 AU AU2008260399A patent/AU2008260399C1/en active Active
- 2008-04-11 PT PT87456158T patent/PT2162149E/pt unknown
- 2008-04-11 KR KR1020207004398A patent/KR102283639B1/ko active IP Right Grant
- 2008-04-11 US US12/602,214 patent/US8222214B2/en active Active
-
2012
- 2012-06-27 US US13/534,550 patent/US8796220B2/en active Active
-
2014
- 2014-01-30 CY CY20141100076T patent/CY1114912T1/el unknown
- 2014-02-05 HR HRP20140102AT patent/HRP20140102T1/hr unknown
- 2014-07-04 JP JP2014138567A patent/JP6097724B2/ja not_active Expired - Fee Related
- 2014-07-09 US US14/327,224 patent/US9370560B2/en active Active
-
2016
- 2016-10-28 JP JP2016211150A patent/JP2017071607A/ja active Pending
-
2018
- 2018-03-05 US US15/912,156 patent/US10842856B2/en active Active
- 2018-08-16 JP JP2018153050A patent/JP7072467B2/ja active Active
-
2020
- 2020-09-25 JP JP2020161232A patent/JP2021001218A/ja active Pending
- 2020-10-21 US US17/076,635 patent/US20220347281A1/en not_active Abandoned
-
2022
- 2022-01-12 US US17/574,178 patent/US20220241389A1/en active Pending
- 2022-04-18 JP JP2022068170A patent/JP2022095926A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529026A5 (ja) | ||
| HRP20140102T1 (hr) | Cjepivo za prevenciju relapsa raka dojke | |
| ES2752248T5 (es) | Heterodímero proteínico y uso del mismo | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| CN107519486B (zh) | 于感染性与恶性疾病的治疗中提升免疫反应的方法 | |
| RU2435782C2 (ru) | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция | |
| JP2014114288A5 (ja) | ||
| Guan et al. | Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis | |
| Wallach et al. | Advances in the treatment of neuromyelitis optica spectrum disorder | |
| JP2012102122A5 (ja) | ||
| CN1304451A (zh) | 结核杆菌抗原融合蛋白及其应用 | |
| JP2003528924A5 (ja) | ||
| WO2017177207A1 (en) | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines | |
| JP2014500278A5 (ja) | ||
| AU2015204503A1 (en) | Novel vaccines against HPV and HPV-related diseases | |
| WO2022016844A1 (zh) | 一种基于干扰素的癌症治疗方法和药物组合 | |
| JP2014506562A5 (ja) | 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用 | |
| Lee et al. | Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination | |
| JP2015520129A (ja) | 多価乳がんワクチン | |
| JP2018522041A (ja) | 改変酵母−ブラキュリー免疫療法組成物 | |
| AU2022201142A1 (en) | Vaccine compositions and methods for restoring NKG2D pathway function against cancers | |
| JP2015517511A5 (ja) | ||
| JP2015526446A5 (ja) | ||
| Melo et al. | Golimumab (anti-TNF monoclonal antibody): where we stand today | |
| Shiohara et al. | Pathomechanisms of lichen planus autoimmunity elicited by cross-reactive T cells |